{"Clinical Trial ID": "NCT00450723", "Intervention": ["INTERVENTION 1:", "Biopsy of sentinel lymph nodes", "[Unspecified]"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "- Breast cancer confirmed histologically", "(T1-T2, N0, M0/MX)", "No tumour invading the chest wall (T3 disease)", "Median or central lesion", "No multicentre disease", "A multifocal disease is allowed.", "No clinically positive axillary ganglion", "No internal breast nodes expanded by CT scan", "Unspecified hormonal receptor status", "CHARACTERISTICS OF PATIENTS:", "Men or women", "\u2022 Menopausal status not specified", "American Society of Anesthesiologists (ASA) Physical Status Classification 1-2", "No pregnancy or breast-feeding", "Negative pregnancy test", "No other known co-occurring, invasive malignancy", "No known chronic lung disease", "No known allergy to methylene blue or isosulfan", "THERAPE PRIOR CONCURENT:", "No previous chest or cardiac surgery", "No previous placement of ipsilateral thoracic tube", "Contralateral placement of the authorized thoracic tube", "No previous neoadjuvant chemotherapy", "No radiotherapy prior to the mediatanum"], "Results": ["Performance measures:", "Success rate in the elimination of sentinel lymph nodes by thoracoscopy", "[Unspecified]", "Time limit: 5 years", "Results 1:", "Title of the arm/group: Sentinel lymph nodes biopsy", "Description of arm/group: [Unspecified]", "Total number of participants analysed: 34", "Type of measurement: Number", "Unit of measure: participants 31"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/34 (0.00 per cent)"]}